{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-317685","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2021-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.596266+00:00","generated_at":"2026-06-28T13:51:02.747897+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Agios Q3 net loss $88.8M; mitapivat gets FDA Priority Review with PDUFA Feb 17, 2022","bullets":["Net loss $88.8M vs $99.0M in Q3 2020; R&D $64.0M up from $51.9M on trial start-up costs.","Cash $1.4B; expects to fund operations through cash-flow positivity without equity raise.","FDA granted Priority Review for mitapivat in PK deficiency; PDUFA date Feb. 17, 2022.","Initiated Phase 3 ENERGIZE and ENERGIZE-T for thalassemia; plan to start RISE UP sickle cell study by year-end.","Repurchased 5.3M shares at $47.94 avg; $800M+ of $1.2B buyback completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-317685","json":"https://secwatch.observer/filing/0001193125-21-317685.json","markdown":"https://secwatch.observer/filing/0001193125-21-317685.md","text":"https://secwatch.observer/filing/0001193125-21-317685.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000119312521317685/0001193125-21-317685-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000119312521317685/d199842d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:51:02.747897+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}